|
|
|
|
| Symbol(s): |
DYAX |
| Date: |
18-Apr-13 |
| Author: |
Hunter Orr |
| Contributor: |
Alpha Street Research |
| Title: |
DYAX - Dyax Corp - Downgraded to a Sell - Research Report by ASR |
| Document Size: |
9 pages |
| Price: |
$24 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $24. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. The Company currently has two recombinant proteins, DX-88 and DX-890 in...
| | |
|
|
